Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial-Reference-Cited by-同舟云学术

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

Published:2016-06 Issue:6 Volume:17 Page:717-726
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Muro Kei,Chung Hyun Cheol,Shankaran Veena,Geva Ravit,Catenacci Daniel,Gupta Shilpa,Eder Joseph Paul,Golan Talia,Le Dung T,Burtness Barbara,McRee Autumn J,Lin Chia-Chi,Pathiraja Kumudu,Lunceford Jared,Emancipator Kenneth,Juco Jonathan,Koshiji Minori,Bang Yung-Jue

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

2. Gastric cancer;Catalano;Crit Rev Oncol Hematol,2009

3. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010

4. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial;Fuchs;Lancet,2014

5. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial;Wilke;Lancet Oncol,2014

Cited by 935 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circ_0001947 encapsulated by small extracellular vesicles promotes gastric cancer progression and anti-PD-1 resistance by modulating CD8+ T cell exhaustion;Journal of Nanobiotechnology;2024-09-14

2. Overall survival prediction of gastric cancer using the gene signature of CT-detected extramural venous invasion combined with M2 macrophages infiltration;Journal of Translational Medicine;2024-09-09

3. Eight types of RNA modification regulators define clinical outcome and immune response in gastric cancer;Heliyon;2024-09

4. The current status of immunotherapy and future horizon in the treatment of metastatic and locally advanced gastroesophageal adenocarcinoma;Expert Opinion on Biological Therapy;2024-08-28

5. Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer;Journal of Translational Medicine;2024-08-21